Dr. Frank Hsu
Jim. Thanks,
updating on our I'll next programs through progress product and more in-depth spend taking look few the minutes you at clinical candidates. our diverse a
designed as for cirmtuzumab, advanced kinase-like Receptor R-O-RX known MCL. in to also which antibody CLL a clinical as Phase or X. most is program is monoclonal combination RORX, patients agent is Our clinical trial the under receptor X/X investigation also tyrosine Orphan currently with in This known with which ibrutinib or evolves inhibit the
data in that to new mantle highlight. have we'd Jim As cell some mentioned, we lymphoma like
has become patients aware, probably the you're As for nerve diseases. these ibrutinib with standard-of-care
of and effective have had agent induce regimens relapsed/refractory response prior Although only treated single to complete indicate more XX%. of patients that or remissions is ibrutinib ability about X data of MCL published and with limited, complete the rates previously
added or an improvement -- ibrutinib substantial CR patients believe of for that may patients. toxicity, provide that number clinical agent little increase to no is achieving there with meaningful be may for room benefit. We Thus, a complements the
refractory cirmtuzumab-ibrutinib XX complete XX% combination in increased with MCL meeting escalation and of to portion with includes the study. response for interim enrolled ASH presented the the we December in from now rate XX% relapsed MCL results of six at this Since patients annual for dose meeting, XXXX, evaluable has patients
who of in CRs XXXX, as are of the months March patient one including six X, ongoing CR cutoff remained on for study. has data All over XX
six on responses evaluating in based response complete a criteria on these by are while four steady, For one a the biopsy standard the Cheson achieved months responses within PET marrow metabolic scan lymphoma patients of was CRs for and pending. bone six with
rate CR response XX% overall X.X the months. cutoff, a of MCL It's the with median with XX% patients to note follow-up increased been interesting XX many patients have data in a the of with these As pretreated. to same heavily that from or response objective partial for has study XX of particularly to patients achieving
chemotherapy; had therapy; patients followed CAR-T and with later therapies of prior autologous autologous was transplant; cell two which enrolled autologous a ibrutinib patients stem a rituximab Overall, transplant, transplant, followed by cell by allogeneic stem who and cell a including median stem transplant before chemotherapy. hyper‐CVAD had Stem participating, consolidation followed received cell by
that XXX% the at who plus rate PR data of the may these expansion of indicate four the enrolling The where further rate, are ibrutinib. into cutoff. MCL. stable disease. are of CRs, stable overall PRs patients and with this now MCL that six very rate, two we is dose patients stands additional believe and encouraging cirmtuzumab safety response cohort of We disease and/or the clinical includes in as patients We're And had the cirmtuzumab benefit complete an recommended examining regimen activity early of with results that efficacy
with ASH study clinical CLL our XXX%. At trial. are from now and a no clinical clinical presented interim rate while all measurable patient meeting X/X experienced had a XXXX, months of enrolling X.X partial remained months to XXXX. of data anti-CLL a encouraging reduction was the patients with discontinuation was randomized disease also cirmtuzumab for the CLL we achieved Most with that a response, in of partial November data ibrutinib at achieved comparing at experienced study, December for remission and the Phase patients One on response disease, of XX for a patient the Every this in median the in of trial ibrutinib XX% complete therapy. early the response benefit progression group. included after lymphocytosis, and this patients for those XX of or cutoff, was as of portion which response least an rate and objective complete Patients the in total patient alone. plus six follow-up completion
of been both, for adverse the no In reported continued well events cirmtuzumab CLL alone. dose-limiting or the consistent discontinuations alone. a cirmtuzumab in the relevant has Interestingly, with MCL in with and with and MCL There combination describing ibrutinib and no of is tolerated higher been of adverse which on toxicities, ibrutinib the studies ibrutinib plus was to in ibrutinib at receiving effect events clinically for side ibrutinib neutropenia, alone XX% CLL, described to when study those in rates be attributed information. cirmtuzumab have it's only study, serious no reported patients ibrutinib reported study
response at response achieved alone XXXX been evaluable into Cancer advanced rate for earlier, observed. the X Of toxicities present metastatic As after regimen weekly for Early also XX%, of four no rate response additional examined the higher the the this has breast Enrollment no building hope unresectable San to treatment the XX-weeks data and is look trial paclitaxel least Jim patients has The late This forward data of in literature. with with study from expected seven investigator-sponsored for patients, or been cirmtuzumab year. in HERX-negative, based published momentum cirmtuzumab on Breast Symposium cirmtuzumab response December and dose paclitaxel. one at of be this for this combination an discontinuation of that at toxicities, combination mentioned and for the objective would the partial well partial was in limiting including in this a cancer. study tolerated locally Phase of with XXXX. paclitaxel, on for continued cirmtuzumab study and present ongoing. of in discontinuing paclitaxel the We scientific trial, clinical venues to is on Antonio
agent factor biologic to a oncoproteins, molecule tumor TKXXX. novel or inhibit Next, designed of with in ETS EXX of the transformation-specific variety to small like I'd clinical our was transcription family discuss This program activity types. the
bone second therapy. and lead medical indication relapsed/refractory compound for rare which systemic Ewing unmet this with standard critical need, is pediatric cancer a Our no line is sarcoma, a
with qualifies CTOS Phase meeting or been relapsed/refractory fast track this And status indication. has of for an Oncology orphan sarcoma. November treatment and X Tissue for from received the as of one FDA the Society orphan presented Connective in on Ewing Ewing of interim designation program. patients investigators sarcoma TKXXX XXXX, the At the our data
of a these in lengths dose XXXX, study, X TKXXX safety for expansion and Based extensively and using Phase and arm of parameters. pharmacokinetic dose different regimen schedule. of data, time the this was was levels we announced a opening recommended December at And dose for In for on this chosen. patient examined
and was subsequently who We for X sustained that clinical have was selected the recommended received deep seen Phase clinical as reported response responses, regimen TKXXX dose. a dose patient
Following pulmonary more several with response XX patient cycles treatment agent, lesions. therapy continued given The objective resolution pre-treated of the as TKXXX of than two young this achieved single heavily which a which response, patient of receiving than in TKXXX with well-tolerated by the included has at confirmed months plus surgical remission. this to leading a was The diameter, later Treatment courses. centimeter TKXXX remaining treatment patient. less been was has a tumor removed, final surgically complete subsequent nodule, vincristine in
forward patients relapsed/refractory to XXXX. to Ewing additional The the in broad with this We targeted potential expansion enroll arm exploring updates novel hope half XX therapy anticipated sarcoma. look second of approximately the is provide to and of the
fragment opportunity to of CAR-T RORX RORX neoplasms, tissues. is CAR-T in cancer recognize solid component hematologic in third but San cells to provides RORX-targeted California, program is bind to the with cancer and normal with of Our development high malignancies, many the preclinical The therapy, of antibody, human targeting present cirmtuzumab new University an is affinity uses indications. target our Diego. including a both, not on which that's and designed to collaboration the different
preclinical and studies, leukemia. these therapy reservoirs of In CAR-T were prolong data antitumor bone activity from [Immuno-Oncology] XXXX, preclinical CAR-T kidneys Symposium. leukemia presented Immunology survival demonstrated cell major and model persistence marrow, in at -- clear expansion, to therapy February spleen. cells (sic) CAR-T including anti-RORX able an RORX the ASCO-SITC RORX tissue we Clinical human In and animal
UC, CIRM. is our under by Diego Institute being Medicine the Regenerative California of or grant San research collaborators from conducted This a
of results and preclinical with We to RORX the into forward this clinic. are the CAR-T it look advancing pleased program
Jim discussion. to over it to further I'd like for now our back turn CEO, Breitmeyer
